We can control the development of metabolic disease by controlling the abnormally elevated levels of liver proteins during the disease, including some ANGPTL family proteins, fetuin-A, heparin, etc. This would control the development of metabolic disease by improving insulin sensitivity and maintaining lipid homeostasis to suppress systemic inflammation and IR. Here, AHSG is linked to metabolic disease.